Oxford, UK, 20 February 2018 – Mirada Medical, a leading global brand in medical imaging software, has released DLCExpert™, the first commercially available software for automatic contouring of CT scans based on the next generation Deep Learning Contouring (DLC).

DLCExpert is Mirada’s first AI based clinical application. It is intended to automate the time consuming clinical task of contouring for treatment planning and bring previously unseen levels of quality and consistency to this process. The inherent gains in efficiency will reduce the time from initial patient consult to start of treatment. High quality and consistently defined structures will allow more confidence when delivering treatment plans.

Unlike prior state-of-the-art algorithms, DLCExpert delivers consistently high-quality structures that have been evaluated as acceptable for clinical use by leading experts in radiation oncology. Utilizing Mirada’s advanced deep learning algorithms, the software uses models that have been trained using image data from prominent academic institutions to automatically generate structures for treatment planning.

Mark Gooding, Mirada’s Chief Scientist comments, “We’re excited to be releasing DLCExpert for clinical use. This is an industry first and it represents a substantial improvement on the state-of-the-art. Autocontouring technology that closely imitates clinical experts will deliver consistently high levels of contouring quality while saving time and resources”.

DLCExpert has regulatory approval in Europe, is pending FDA clearance in the USA, and has been clinically validated by the Department of Radiation Oncology of the Maastro Clinic in Maastricht, The Netherlands. Their results have been accepted for publication by Radiotherapy and Oncology, a key clinical peer-reviewed European journal.

Andre Dekker, Professor of Clinical Data Science states, “The contours generated by DLCExpert are the closest to clinically acceptable contours we’ve seen from any autocontouring system we have evaluated. For some organs, our clinicians found it very hard to distinguish between their own contours and those that were automatically generated”.

Hugh Bettesworth, Mirada’s CEO adds, “We have taken advantage of cutting edge AI technology to address one of the everyday clinical needs in Radiation Oncology. At Mirada we are committed to working with cancer treatment providers to offer more and better treatment options for their patients. The launch of DLCExpert is another example of this commitment”.

About Mirada Medical
Mirada is a leading international brand that develops software applications that simplify solutions to complex image analysis problems in the diagnosis and treatment of cancer. Through automation, our products improve consistency and productivity while enabling clinicians to deliver more personalized care. By combining deep learning technology with our thorough understanding of the challenges faced in oncology today, Mirada is leading the development of next generation imaging software and decision support products. Our staff are passionate about using their expertise to help our customers provide better healthcare for more patients.